A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. [electronic resource]
Producer: 20140311Description: 721-8 p. digitalISSN:- 1463-1326
- Adult
- Aged
- Aged, 80 and over
- Argentina -- epidemiology
- Benzhydryl Compounds -- administration & dosage
- Blood Glucose
- Body Weight
- Diabetes Mellitus, Type 2 -- blood
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Europe -- epidemiology
- Female
- Glucosides -- administration & dosage
- Glycated Hemoglobin -- metabolism
- Humans
- Hypoglycemic Agents -- administration & dosage
- Male
- Metformin -- administration & dosage
- Middle Aged
- Nasopharyngitis -- chemically induced
- Republic of Korea -- epidemiology
- Russia -- epidemiology
- Sodium-Glucose Transporter 2 Inhibitors
- Taiwan -- epidemiology
- Thirst
- Treatment Outcome
- Ukraine -- epidemiology
- Urination Disorders -- chemically induced
- Weight Loss
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.